Cardiovascular Complications in Patients with Klinefelter’s Syndrome

Author(s): Franz Sesti, Riccardo Pofi, Carlotta Pozza, Marianna Minnetti, Daniele Gianfrilli, George A. Kanakis*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 43 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

More than 70 years have passed since the first description of Klinefelter Syndrome (KS), the most frequent chromosome disorder causing male infertility and hypogonadism. KS is associated with increased cardiovascular (CV) mortality due to several comorbidities, including hypogonadism, as well as metabolic syndrome and type 2 diabetes, which are highly prevalent in these patients. Aside from metabolic disturbances, patients with KS suffer from both acquired and congenital CV abnormalities, cerebrovascular thromboembolic disease, subclinical atherosclerosis and endothelial dysfunction, which may all contribute to increased CV mortality. The mechanisms involved in this increased risk of CV morbidity and mortality are not entirely understood. More research is needed to better characterise the CV manifestations, elucidate the pathophysiological mechanisms and define the contribution of testosterone replacement to restoring CV health in KS patients. This review explores the complex association between KS, metabolic syndrome and CV risk in order to plan future studies and improve strategies to reduce mortality in this high-risk population.

Keywords: Klinefelter syndrome, cardiovascular diseases, hypogonadism, cardiac abnormalities, metabolic syndrome, cardiovascular risk, thromboembolic disease.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 43
Year: 2020
Published on: 22 December, 2020
Page: [5556 - 5563]
Pages: 8
DOI: 10.2174/1381612826666201102105408
Price: $65

Article Metrics

PDF: 15